Gene · 7398
Papers1,534
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
21 to 40 of 1,534
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Discovery of a Potent Fluorescence Polarization Probe for Identifying USP1 Allosteric Inhibitors. | Adv Sci (Weinh) | 2026 | 42017803 | PubTator, text mining | PubMed |
| Discovery and optimization of 1H-pyrazolo[3,4-d]pyrimidine-3-carboxamide derivatives as USP1 inhibitors for BRCA1-mutant cancer treatment. | Bioorg Chem | 2026 | 41950717 | PubTator, text mining | PubMed |
| Development and validation of a highly accurate multigene gene expression biomarker to predict chemotherapy response in primary triple-negative breast cancer. | Breast Cancer Res Treat | 2026 | 41885969 | PubTator, text mining | PubMed |
| Molecular mechanisms of NLRP3 inflammasome activation. | Exp Mol Med | 2026 | 41876821 | PubTator, text mining | PubMed |
| A Novel Insight into Chronic Pancreatitis Pathogenesis: the USP1/ITGB5 Axis-Mediated Stellate Cell Activation. | Inflammation | 2026 | 41857463 | PubTator, text mining | PubMed |
| SERBP1 is required for efficient HR repair and cisplatin chemoresistance in lung adenocarcinoma. | Cell Death Discov | 2026 | 41856985 | PubTator, text mining | PubMed |
| PLAAT2 suppresses gastric cancer progression by facilitating cMyc ubiquitination and inhibiting MEK/ERK signaling. | Cell Death Dis | 2026 | 41851102 | PubTator, text mining | PubMed |
| Synthesis of Novel USP1 Inhibitors and Their Uses in Treatment of USP1 Related Diseases. | ACS Med Chem Lett | 2026 | 41847635 | PubTator, text mining | PubMed |
| USP1 driven mitotic dysregulation and PLK1 stabilization confer Lenvatinib resistance in hepatocellular carcinoma. | J Exp Clin Cancer Res | 2026 | 41820949 | PubTator, text mining | PubMed |
| USP10 regulates HIF2α stability by deubiquitinating HIF2α regardless of VHL status in kidney cancer. | Transl Androl Urol | 2026 | 41809792 | PubTator, text mining | PubMed |
| Disrupting the USP1-UAF1 deubiquitinase complex: a master regulator of replication stress and frontier target in cancer therapy. | Med Oncol | 2026 | 41801511 | PubTator, text mining | PubMed |
| USP1 promotes hepatocellular carcinoma progression by modulating mitophagy via stabilizing MCM3 to regulate the Keap1-Nrf2 axis. | iScience | 2026 | 41797940 | PubTator, text mining | PubMed |
| Molecular Characteristics, Potential Mechanisms, and Prognostic Gene Model of Younger Female Patients With Gastric Cancer. | Cancer Rep (Hoboken) | 2026 | 41773524 | PubTator, text mining | PubMed |
| BCAAs and related metabolic enzymes: partners in crime driving tumor development. | Front Cell Dev Biol | 2026 | 41769003 | PubTator, text mining | PubMed |
| USP5-mediated CD73 deubiquitination drives osimertinib resistance via PI3K/AKT and glycolysis activation in LUAD. | iScience | 2026 | 41767275 | PubTator, text mining | PubMed |
| Synergistic Cellular Toxicity from Inhibition of Poly(ADP-ribose) Glycohydrolase (PARG) and Ubiquitin-Specific Protease 1 (USP1). | Toxics | 2026 | 41745836 | PubTator, text mining | PubMed |
| Metabolic checkpoints in the regulation of Th17 cells: implications for uveitis pathogenesis and therapy. | Front Immunol | 2026 | 41743733 | PubTator, text mining | PubMed |
| Mechanistic insights into triclosan-induced hepatotoxicity: A network toxicology and molecular docking approach. | PLoS One | 2026 | 41739763 | PubTator, text mining | PubMed |
| Advancing inducible gene-inactivation systems to explore synthetic lethality. | NAR Cancer | 2026 | 41736896 | PubTator, text mining | PubMed |
| ECM remodeling-associated immune signatures and hub proteins: predictive markers and therapeutic targets for metastatic gastric cancer. | Front Immunol | 2026 | 41727482 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/7398/papers?page=2